WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Apr 29, 2026 02:40 UTC
-
Experimental drug shows promise for rare blood cancer
Disease control CompletedThis study tested the drug carfilzomib in 7 people with Waldenström's macroglobulinemia, a rare blood cancer, that had come back after previous treatment. The goal was to see if the drug could shrink tumors and control the disease. Carfilzomib works by blocking a protein that cel…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Apr 29, 2026 02:38 UTC
-
New hope for lymphoma patients who suffered side effects from standard drugs
Disease control CompletedThis study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had to stop their previous treatments (ibrutinib or acalabrutinib) because of bad side effects. The main goal was to see…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 29, 2026 02:38 UTC